The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer: An update on recurrence-free survival and correlative biomarkers.
 
Marco de Bruyn
Stock and Other Ownership Interests - Sairopa
Research Funding - Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - Patent CD103 antibodies
 
Anneke L. Eerkens
No Relationships to Disclose
 
Koen Brummel
No Relationships to Disclose
 
Annegé Vledder
No Relationships to Disclose
 
Sterre T. Paijens
No Relationships to Disclose
 
Marta Requesens
No Relationships to Disclose
 
Dominik Loiero
No Relationships to Disclose
 
Nienke van Rooij
No Relationships to Disclose
 
Annechien Plat
No Relationships to Disclose
 
Floris-Jan R. Haan
No Relationships to Disclose
 
Patty Klok
No Relationships to Disclose
 
David Church
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Consulting or Advisory Role - MSD
Research Funding - HalioDx (Inst)
 
René Wardenaar
No Relationships to Disclose
 
Floris Foijer
No Relationships to Disclose
 
Viktor Koelzer
Employment - University Hospital of Zürich
Consulting or Advisory Role - VHK is on an advisory board of Takeda (unrelated to the content of this study) and member of the European Key Opinion Leader Network in Digital Pathology supported by Roche.
Speakers' Bureau - VHK has acted as an invited speaker for Sharing Progress in Cancer Care (a non-profit educational organization) and Indica Labs unrelated to the content of this study..
Research Funding - VHK holds sponsored research agreements with Roche and IAG unrelated to the content of this study.
Patents, Royalties, Other Intellectual Property - VHK is participant of a patent application co-owned by the Netherlands Cancer Institute (NKI-AVL) and the University of Basel on “Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy” (Filing No. N
Travel, Accommodations, Expenses - VHK is on an advisory board of Takeda (unrelated to the content of this study) and member of the European Key Opinion Leader Network in Digital Pathology supported by Roche.
 
Tjalling Bosse
No Relationships to Disclose
 
Jos Bart
Research Funding - AstraZeneca
 
Mathilde Jalving
Honoraria - Pierre Fabre
 
An K.L Reyners
No Relationships to Disclose
 
Hans Nijman
Stock and Other Ownership Interests - Sairopa; ViciniVax
Patents, Royalties, Other Intellectual Property - Patent CD103 antibodies